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The XIII Banff meeting, held in conjunction the Cana-
dian Society of Transplantation in Vancouver,
Canada, reviewed the clinical impact of updates of
C4d-negative antibody-mediated rejection (ABMR)
from the 2013 meeting, reports from active Banff
Working Groups, the relationships of donor-specific
antibody tests (anti-HLA and non-HLA) with trans-
plant histopathology, and questions of molecular
transplant diagnostics. The use of transcriptome
gene sets, their resultant diagnostic classifiers, or
common key genes to supplement the diagnosis and
classification of rejection requires further consensus
agreement and validation in biopsies. Newly
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introduced concepts include the i-IFTA score, com-
prising inflammation within areas of fibrosis and
atrophy and acceptance of transplant arteriolopathy
within the descriptions of chronic active T cell–medi-
ated rejection (TCMR) or chronic ABMR. The pattern
of mixed TCMR and ABMR was increasingly recog-
nized. This report also includes improved definitions
of TCMR and ABMR in pancreas transplants with
specification of vascular lesions and prospects for
defining a vascularized composite allograft rejection
classification. The goal of the Banff process is ongo-
ing integration of advances in histologic, serologic,
and molecular diagnostic techniques to produce a
consensus-based reporting system that offers precise
composite scores, accurate routine diagnostics, and
applicability to next-generation clinical trials.
Abbreviations: aah, hyaline arteriolar thickening; ah,
arteriorlar hyalinosis; ABMR, antibody-mediated
rejection; ASHI, American Society for Histocompati-
bility and Immunogenetics; BWG, Banff Working
Groups; cg, glomerular double contours; ci, intersti-
tial fibrosis; ct, tubular atrophy; cv, vascular fibrous
intimal thickening; DGF, delayed graft function; DSA,
donor-specific antibody; DSAST, donor-specific
antibody–specific transcript; ELISA, enzyme-linked
immunosorbent assay; EM, electron microscopy;
FDA, U.S. Food and Drug Administration; FFPE, for-
malin-fixed, paraffin-embedded; g, glomerulitis;
GBM, glomerular basement membrane; HS, highly
sensitized; i, inflammation; IFTA, interstitial fibrosis
and tubular atrophy; i-IFTA, interstitial inflammation
in areas of interstitial fibrosis and tubular atrophy;
IHC, immunohistochemistry; IVIG, intravenous
immunoglobulin; mRNA, messenger RNA; miRNA,
microRNA; MPGN, membranoproliferative glomeru-
lonephritis; MVI, microvascular invasion; PAS, peri-
odic acid–Schiff; PCR, polymerase chain reaction; ptc,
peritubular capillaritis; PTC, peritubular capillary; t,
tubulitis; TCMR, T cell–mediated rejection; TG, trans-
plant glomerulopathy; ti, total inflammation; TMA,
thrombotic microangiopathy; v, intimal arteritis;
VCA, vascularized composite allograft
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Introduction
The XIII Banff meeting was held October 5–10, 2015, in
Vancouver, Canada, in conjunction with the annual meet-
ing of the Canadian Society of Transplantation. A total of
451 delegates from 28 countries attended the confer-
ence, including pathologists, immunologists, physicians,
surgeons, and immunogeneticists. The main aims of the
2015 conference were to review the clinical impact of
the 2013 changes related to the new diagnostic criteria
for antibody-mediated rejection (ABMR) (1) and to iden-
tify the next set of challenges in transplant diagnostics.
Given the limitations of the current Banff system, a need
for a more integrated diagnostic system, including
complementary approaches as a companion to the
current morphologic gold standard, are needed. Conse-
quently, the prospects for introducing molecular diagnos-
tics into the Banff classification were a main focus.
Accordingly, the Banff 2015 conference was preceded
by a full-day premeeting on “Precision Diagnostics” in
transplantation. This included presentations from key
opinion leaders of the American Society for Histocompat-
ibility and Immunogenetics (ASHI) with the aim to foster
collaboration between the societies in transplant diagnos-
tics. This meeting report summarizes the main outcomes
from the Banff kidney, pancreas, and vascularized com-
posite allograft (VCA) sessions; the main conclusions
from the 2015 Banff liver, heart, and lung sessions will
be published elsewhere. The XIV Banff meeting will be
held jointly with the Catalan Society of Transplantation in
Barcelona, Spain, March 27–31, 2017.
Results From the Banff Working Groups
and New Developments
Banff Working Groups (BWGs) have been formed at
each of the last four Banff conferences to address and
potentially modify specific aspects of the classification
(2). Their activities are dynamic and goal directed; there-
fore, the Banff community decided during the 2015
conference to close or suspend working groups whose
work has been completed and published, in press, and/
or incorporated into the classification (isolated endarteri-
tis, Banff Initiative for Quality Assurance in Transplanta-
tion, fibrosis, implantation biopsy, polyoma virus, C4d-
negative ABMR, and glomerular lesions BWGs) (1,3–7).
The BWG on highly sensitized patients presented the
results of three surveys of pathologists, clinicians, and
histocompatibility laboratory directors, comprising 193
centers from six continents, and revealed wide hetero-
geneity among participating centers regarding immune
modulation/desensitization practices, timing of kidney
allograft protocol biopsies, and testing and reporting of
HLA antibody and donor-specific antibody (DSA) levels.
The TCMR working group’s main aims and related
ongoing studies are detailed in Table 1 and are
expected to provide novel insights by the next Banff
meeting.
Four new BWGs have been formed: (i) thrombotic
microangiopathy, (ii) recurrent glomerular diseases,
(iii) diagnostic electron microscopy, and (iv) composite
surrogate end points. The aim of the latter BWG is to
build and validate a composite scoring system integrating
histopathology with other relevant allograft biomarkers to
predict long-term allograft outcome as a potential end
point for next-generation clinical trials in the area. The
currently active and new working groups and their aims,
leaders, initial findings (if appropriate), and ongoing work
are listed in Table 1. As an outlook on future challenges,
the Banff process founder Kim Solez gave a keynote
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address on tissue engineering pathology, a new pathol-
ogy discipline that will likely play an increasing role in
future Banff meetings, as transplant pathologists need to
embrace tissue engineering pathology in the era of
regenerative medicine (8).
New Challenges in Rejection Diagnosis and
Classification
During the 2015 Banff conference, there was lively dis-
cussion about diagnostic concerns regarding ABMR, T
Table 1: Summary of active Banff 2015 working groups
Leaders Issues to address Group findings/plans
TCMR V. Nickeleit,
P. Randhawa
Possible incorporation of i-IFTA into classification;
possible elimination of borderline category;
reevaluate thresholds for inflammation and t
and possible addition of other findings (e.g.
edema) to TCMR diagnostic criteria
Group currently collecting cases of
“pure” TCMR (no DSA or C4d) for
pathologic evaluation and
clinicopathologic correlation
Sensitized L. Cornell, E. Kraus,
S. Bagnasco,
C. Schinstock,
D. Dadhania
Define criteria for HS patients, determine
consensus for what personnel and facilities are
needed for centers to perform transplantation in
HS recipients, standardize the definitions
related to management of sensitized transplant
recipients
Survey results presented by L. Cornell
at 2015 Banff conference; expanded
survey, future discussions to address
core issues; prepare consensus paper
for publication
Molecular M. Mengel, B. Sis Develop consensus guidelines for circumstances
under which it is advisable to apply molecular
analysis to renal biopsy tissue and/or serum/
urine collected at the time of biopsy; determine
the best molecular studies to perform with the
aim of generating the needed evidence for
adoption of molecular diagnostics into the Banff
classification; standardize diagnostic criteria for
molecular microscope
Single-center data using the NanoString
method on FFPE tissue presented by
Banu Sis at the Banff 2015
conference; validation needed of
biopsies from additional centers
Electron
microscopy
C. Roufosse,
H.K. Singh
Interobserver variability and clinical correlations in
cg1a lesions and ptcml scoring; potential
refinement of ptcml scoring criteria; criteria for
amount of GBM reduplication and immune
complex-type deposits allowable in cg1a;
multicenter study of the natural history,
associations, and predictive value of cg1a and
ptcml using consensus criteria
Survey of current practice completed
June 2016; circulation of images for
interobserver reproducibility, fall
2016; multicenter study 2017–2018
TMA1 M. Afrouzian,
J. Becker,
H. Liapis,
S. Seshan
Generate consensus regarding diagnostic criteria
for TMA in renal allografts using histopathology/
laboratory data/molecular genetics correlation
Survey 1 circulated in January 2016;
results have been shared with the
working group participants.
Plan: TMA experts defined and
identified; will collect 30 cases;
generate virtual slides and run digital
evaluation
Recurrent
glomerular
disease1
N. Alachkar Focus on glomerulopathies: IgA nephropathy,
FSGS, MPGN/C3 glomerulopathy; what are
frequencies, clinical manifestations, and
pathologic characteristics of recurrent/de novo
disease? Can any of these predict recurrence
and/or graft outcomes?
New working group
Composite
surrogate
end points1
A. Loupy,
B. Orandi
Respond to the unmet need raised by the FDA
meeting held in Arlington, Virginia, in 2015:
Build a validated multicenter composite scoring
system integrating histopathology with other
relevant allograft biomarkers to predict long-
term allograft outcome
New working group
cg, glomerular double contours; DSA, donor-specific antibody; FDA, U.S. Food and Drug Administration; FFPE, formalin-fixed, paraffin-
embedded; FSGS, focal segmental glomerulosclerosis; GBM, glomerular basement membrane; HS, highly sensitized; i-IFTA, interstitial
inflammation in areas of interstitial fibrosis and tubular atrophy; MPGN, membranoproliferative glomerulonephritis; ptcml, peritubular
capillary basement membrane multilayering; t, tubulitis; TCMR, T cell–mediated rejection; TMA, thrombotic microangiopathy.
1New working group.
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cell–mediated rejection (TCMR), and mixed rejection in
renal allografts. Important new data were presented
revealing the heterogeneity of clinical expression of
ABMR with consequent difficulties for diagnosis. In addi-
tion, important insights were presented by ASHI mem-
bers on how testing for DSAs and interpretation of
results should be included in the Banff classification
(Table 2).
Recent evidence indicates that subclinical ABMR has
important clinical implications, even in non–highly sensi-
tized patients with de novo DSAs (9). As noted by Orandi
et al, “Increasing numbers of transplant physicians are
encountering this problem, which may become more
common given new therapeutic agents and new organ
allocation policies” (10).
A growing number of centers perform high-risk renal
transplants, thereby intensifying the need for improved
assessment of subclinical ABMR (11) and the clinical
implications of its kinetics and response to therapy
(10). Advances in antibody testing by multiplex bead
array assays have greatly enhanced the sensitivity and
precision of detection of circulating DSAs (12). Accu-
mulating evidence supports the concept that not all
DSAs are equivalent and that DSA properties (ability
to bind complement or IgG subclass), beyond simple
positivity and mean fluorescence intensity, are associ-
ated with distinct outcomes and injury phenotypes in
preexisting or recurrent as well as de novo DSAs (13–
20). These distinct DSA properties and their relation-
ship with distinct allograft injury patterns is also
increasingly demonstrated in other solid organ
transplants such as liver (21) and heart (22). It was
also noted that time course, kinetics, and properties
of DSA fluctuate (15,23). Consequently, interpretation
of studies evaluating sera at a single time point, espe-
cially late after transplantation, should be interpreted
with caution because of potential selection bias
(24,25). Despite the usefulness of multiplex bead array
assays, inherent limitations, technical issues, and lack
of available DSA data at the time of biopsy make
diagnoses complex. It was reemphasized that non–
anti-HLA DSAs can produce allograft injury alone or
together with anti-HLA DSAs (26–28). These observa-
tions raise the question of whether ABMR can be
diagnosed in the absence of documented DSAs based
on ABMR-related pathology only, namely, microcircula-
tion inflammation, C4d deposition, and vasculitis with
or without increased expression of DSA-associated
gene sets (29,30).
Furthermore, many cases of ABMR in renal allografts,
particularly late ABMR associated with de novo DSAs,
can present as mixed ABMR and TCMR (31). Renal
allograft biopsies with microvascular inflammation plus
intimal arteritis also frequently show tubulointerstitial
TCMR changes (9,32). These cases likely represent
mixed ABMR and TCMR and, not surprisingly, are
often not responsive to treatment for either ABMR or
TCMR alone (32,33). This may be related in large part
to the fact that many cases of late ABMR are associ-
ated with nonadherence (34). TCMR is also a docu-
mented predisposing factor for the future development
of de novo DSAs, as demonstrated in two recent stud-
ies (9,11). More data are needed regarding transplant
glomerulopathy (TG) or double contours with or without
microcirculation inflammation in terms of disease activ-
ity and progression and thus necessity of treatment. A
key question discussed during the meeting was
whether patients with TG should be treated for active
ABMR or whether it should be accepted that these
patients will progress to graft loss regardless of treat-
ment. A study by Kahwaji et al (35) showed in a small
cohort of patients, all with TG, that those with active
microvascular invasion (MVI) were significantly more
likely to show stabilization of graft function with intra-
venous immunoglobulin (IVIG) and rituximab than
patients with similar histology who were not treated,
whereas patients with TG without active MVI did not
benefit from treatment with IVIG and rituximab. The
findings suggest that the decision as to whether to
treat patients with TG, particularly those with DSAs,
should depend on whether there is concurrent active
MVI. More recently, a pilot randomized control trial
showed that patients with chronic ABMR that
responded to complement blockade eculizumab by
improved GFR were the ones that had complement
(C1q binding) circulating anti-HLA DSAs at the time of
diagnosis (36). This important issue will be addressed
further at Banff 2017.
Table 2: Key points addressed by the American Society for
Histocompatibility and Immunogenetics expert panel during the
Banff 2015 conference for improving the current diagnostic
system
Key points
Comprehensive typing of recipient and donor is required to
determine presence of HLA-DSA (HLA-A, -B, -C, -DRB1,
-DRB3/4/5, -DQA1, -DQB1, -DPA1, -DPB1).
Determine DSA specificity at the allelic level (including DQA and
DQB and for other loci when allelic-specific antibodies are
present).
Recognize the assay limitations and minimize the inherent
issues with reagents and patient sera when DSA specificity
and level are considered:
• Inhibition in the presence of intrinsic or extrinsic factors
• Oversaturation of single antigen beads
• Denatured or cryptic epitopes that are not clinically relevant
• Identification of all donor HLA antigens in the assay platform
used to demonstrate the presence of DSA
Correlation of DSA with biopsy findings including molecular data
should incorporate some quantitation of antibody level to
better estimate DSA burden.
DSA, donor-specific antibody.
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DSA Against HLA or Other Antigens in the
Diagnosis of ABMR
The Banff 2013 classification requires the presence of
“serologic evidence of DSA against HLA or other anti-
gens” (criterion 3) for diagnosis of both acute/active and
chronic active ABMR; however, peritubular capillary C4d
deposition is highly specific for DSA and potentially iden-
tifies antibodies against endothelial antigens and DSA
currently not tested for in many laboratories (e.g. anti-
bodies to HLA DP, non-HLA antigens). Furthermore, a
recent study showed similar graft outcomes, at least in
chronic active ABMR, in cases with C4d or DSA and
those with C4d and DSA (37). The attendees of kidney-
specific sessions at Banff 2015 were polled as to
whether the requirement for DSA for diagnosis of ABMR
can be waived in biopsies showing both morphologic evi-
dence of acute or chronic tissue injury (as defined in cri-
terion 1 of the Banff 2013 classification for acute/active
and chronic active ABMR, respectively) and C4d staining
in peritubular capillaries; however, the opinion of the
majority of the Banff panel (with some dissenters) was
that this was not warranted by the current data. It was
instead decided to add the following phrase to the classi-
fication for both acute/active and chronic active ABMR,
as a corollary to criterion 3: “Biopsies meeting the above
histologic criteria and showing diffuse or focal linear per-
itubular capillary C4d staining on frozen or paraffin sec-
tions are associated with a high probability of ABMR and
should [undergo] prompt expedited DSA testing.”.
Table 3 summarizes this new addition to the classifica-
tion, and the complete and most updated Banff classifi-
cations for renal allograft diagnoses are shown in
Table 3.
A set of transcripts (DSA-specific transcripts [DSASTs])
was determined to be differentially expressed in renal
allograft biopsies from DSA-positive versus -negative
patients (29), a finding that was later confirmed indepen-
dently at a different center (30). Consequently, DSASTs
have the potential to identify cases of ABMR in patients
with non-detectable HLA DSA. It is not clear to what
extent, if any, transcript patterns will be affected by
prognostically different DSAs, including anti-HLA class I
versus class II; antibodies with high versus low mean
fluorescence intensity; complement-binding versus
non–complement-binding antibodies (15–17,19); and
antibodies of different IgG subclasses (24). Further
prospective validation is required.
Chronic Active TCMR and Interstitial
Inflammation in Areas of Interstitial
Fibrosis and Tubular Atrophy
The most recent Banff criteria for chronic active TCMR
(38) list only vascular lesions (arterial intimal fibrosis with
mononuclear cell infiltration within the sclerotic intima;
transplant arteriopathy) (Table 3). This is likely neither
complete nor fully accurate; however, sufficient data are
currently not available to properly define this diagnosis.
Interstitial inflammation in areas of interstitial fibrosis and
tubular atrophy (i-IFTA) was discussed among partici-
pants of the Banff meeting as a potential lesion of
chronic active TCMR. Although the association of i-IFTA
with decreased graft survival is well documented (39–
41), the pathogenesis of i-IFTA and to what extent this
represents a manifestation of TCMR is much less clear.
Similarly, the significance of tubulitis in atrophic tubules
is unclear. Gene expression studies on microdissected
foci of i-IFTA might help assess this. In light of the estab-
lished deleterious effect on graft survival of i-IFTA and
IFTA with Banff inflammation (i) score >0, it was agreed
that i-IFTA should be included as part of the Banff lesion
scoring. Moreover, i-IFTA should be graded as mild, mod-
erate, or severe based on whether it involves 10–25%,
26–50%, or >50%, respectively, of the scarred cortical
tissue (Table 4, and supplementary material for scoring
criteria). Note that the extent of i-IFTA is not analogous
to the Banff total inflammation score, the latter repre-
senting the sum of inflammation in scarred and non-
scarred areas of the cortex. Consequently, it was
decided to modify the Banff 2007 criteria by adding a
statement (Table 3, category 4), reflecting findings that
lesions of transplant arteriopathy may represent chronic
active ABMR (42) as well as TCMR—also shown in
experimental studies (43)—and that chronic active TCMR
may also be manifest in the tubulointerstitial compart-
ment.
During the postmeeting discussion, it was clearly articu-
lated that further studies are needed to understand the
significance of i-IFTA in the context of chronic active
TCMR before i-IFTA can be included as a diagnostic crite-
rion. In particular, the ongoing work of the borderline/
TCMR BWG is expected to generate relevant data in this
context.
Prospects for Adopting Molecular
Pathology in Renal Allograft Diagnosis
As part of the 2013 revision of the Banff classification for
diagnosing ABMR, molecular assessment of transcripts
indicative of endothelial injury in the renal allograft biopsy
was added as a potential diagnostic criterion (1); how-
ever, there is no consensus on which transcripts are
diagnostic or on the criteria for positivity. Standards for
platforms, methods, and reproducibility for such molecu-
lar diagnostic assays have not yet been set; such stan-
dards are a requirement for robust clinical validation and
adoption in diagnostic pathology laboratories. During the
2015 Banff premeeting on “Precision Diagnostics in
Transplantation,” current knowledge in the area of
molecular transplant diagnostics was reviewed. State-of-
the-art presentations on molecular diagnostics in allograft
32 American Journal of Transplantation 2017; 17: 28–41
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biopsies and body fluids revealed that significant com-
monalities exist with regard to the molecular phenotype
in transplant biopsies from different organ types (44). In
addition, overlap exists with molecular signatures found
in body fluids (45). In contrast, there is considerable
heterogeneity among published studies with regard to
Table 3: Updated 2015 Banff classification categories
Category 1: Normal biopsy or nonspecific changes
Category 2: Antibody-mediated changes
Acute/active ABMR All three features must be present for diagnosis. Biopsies showing histological features plus evidence of
current/recent antibody interaction with vascular endothelium or DSA, but not both, may be designated as
suspicious for acute/active ABMR. Lesions may be clinically acute or smoldering or may be subclinical; it
should be noted if the lesion is C4d-positive or C4d-negative, based on the following criteria:
1 Histologic evidence of acute tissue injury, including one or more of the following:
 Microvascular inflammation (g >0 in the absence of recurrent or de novo glomerulonephritis, and/or
ptc >0)
 Intimal or transmural arteritis (v >0)1
 Acute thrombotic microangiopathy in the absence of any other cause
 Acute tubular injury in the absence of any other apparent cause
2 Evidence of current/recent antibody interaction with vascular endothelium, including at least one of the
following:
 Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections or C4d >0 by
IHC on paraffin sections)
 At least moderate microvascular inflammation ([g + ptc] ≥2), although in the presence of acute
TCMR, borderline infiltrate, or infection; ptc ≥2 alone is not sufficient, and g must be ≥1
 Increased expression of gene transcripts in the biopsy tissue indicative of endothelial injury, if thor-
oughly validated
3 Serologic evidence of DSAs (HLA or other antigens)
 Biopsies suspicious for ABMR on the basis of meeting criteria 1 and 2 should prompt expedited
DSA testing
Chronic active ABMR2 All three features must be present for diagnosis. As with acute/active ABMR, biopsies showing histological
features plus evidence of current/recent antibody interaction with vascular endothelium or DSA, but not
both, may be designated as suspicious, and it should be noted if the lesion is C4d-positive or C4d-
negative, based on the criteria listed:
1 Histologic evidence of chronic tissue injury, including one or more of the following:
 TG (cg >0), if no evidence of chronic thrombotic microangiopathy; includes changes evident by EM
only (cg1a; Table 4)
 Severe peritubular capillary basement membrane multilayering (requires EM)3
 Arterial intimal fibrosis of new onset, excluding other causes; leukocytes within the sclerotic intima
favor chronic ABMR if there is no prior history of biopsy-proven TCMR with arterial involvement but
are not required
2 Evidence of current/recent antibody interaction with vascular endothelium, including at least one of the
following:
 Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or C4d >0 by
IHC on paraffin sections)
 At least moderate microvascular inflammation ([g + ptc] ≥2), although in the presence of acute
TCMR, borderline infiltrate, or infection, ptc ≥2 alone is not sufficient and g must be ≥1
 Increased expression of gene transcripts in the biopsy tissue indicative of endothelial injury, if thor-
oughly validated
3 Serologic evidence of DSAs (HLA or other antigens):
 Biopsies suspicious for ABMR on the basis of meeting criteria 1 and 2 should prompt expedited
DSA testing
C4d staining without
evidence of rejection
All three features must be present for diagnosis4
1 Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or C4d >0 by IHC
on paraffin sections)
2 g = 0, ptc = 0, cg = 0 (by light microscopy and by EM if available), v = 0; no TMA, no peritubular capillary
basement membrane multilayering, no acute tubular injury (in the absence of another apparent cause for this)
3 No acute cell-mediated rejection (Banff 1997 type 1A or greater) or borderline changes
Category 3: Borderline changes
Suspicious for
acute TCMR
 Foci of tubulitis (t1, t2, or t3) with minor interstitial inflammation (i0 or i1) or interstitial inflammation (i2,
i3) with mild (t1) tubulitis; retaining the i1 threshold for borderline from Banff 2005 is permitted although
this must be made transparent in reports and publications
 No intimal arteritis (v = 0)
(Continued )
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how the molecular phenotype has been assessed and
applied as a potential diagnostic and/or predictive tool
(46). Over the last decade, transplant biopsies, blood,
and urine have been studied comprehensively, primarily
using transcriptomics, and have led to novel insights into
the molecular phenotypes of organ transplants (47–53).
Current ongoing studies—for example, the INTERCOM
studies (47,48)—are assessing a molecular microscope
approach in real time for examining kidney allograft biop-
sies and comparing the gene expression classifiers and
diagnosis to the current gold standard histopathology.
This represents a step forward and will generate impor-
tant results to help guide integration of molecular analy-
sis with morphology. Accordingly, at the 2015 Banff
meeting, converging opinion was supported by recent
data (50,53) that molecular transplantation pathology is at
the point where it can be translated into clinically rele-
vant and applicable diagnostic tools. The obstacles to be
overcome lie in (i) the lack of a true diagnostic gold stan-
dard against which new molecular diagnostics can be
compared and calibrated (there is no gold standard for
serology or histology either); (ii) the fact that data have
been generated from heterogeneous cohorts with diag-
nostic labels assigned based on different iterations of the
Banff classification; (iii) the absence of completed
prospective, controlled, randomized validation studies;
and (iv) the lack of agreement on the transcripts to be
measured and how to measure them.
Most disease processes operating in organ transplants
represent a spectrum of certain biological processes.
Accordingly, our current diagnostic criteria (e.g. for TCMR
and ABMR) are built on semiquantitative diagnostic
thresholds of lesions associated with a certain
phenotype. Such thresholds aim to represent the optimal
trade-off between side effects of enhanced treatment
Table 3. Continued
Category 4: TCMR
Acute TCMR Grade IA. Significant interstitial inflammation (>25% of nonsclerotic cortical parenchyma, i2 or i3) and foci of mod-
erate tubulitis (t2)
IB. Significant interstitial inflammation (>25% of nonsclerotic cortical parenchyma, i2 or i3) and foci of sev-
ere tubulitis (t3)
IIA. Mild to moderate intimal arteritis (v1) with or without interstitial inflammation and tubulitis
IIB. Severe intimal arteritis comprising >25% of the luminal area (v2) with or without interstitial inflamma-
tion and tubulitis
III. Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with
accompanying lymphocytic inflammation (v3)
Chronic active TCMR Chronic allograft arteriopathy (arterial intimal fibrosis with mononuclear cell infiltration in fibrosis, formation
of neointima); note that such lesions may represent chronic active ABMR as well as TCMR; the latter
may also be manifest in the tubulointerstitial compartment
Category 5: Interstitial fibrosis and tubular atrophy
Grade I. Mild interstitial fibrosis and tubular atrophy (≤25% of cortical area)
II. Moderate interstitial fibrosis and tubular atrophy (26–50% of cortical area)
III. Severe interstitial fibrosis and tubular atrophy (>50% of cortical area)
Category 6: Other changes not considered to be caused by acute or chronic rejection
BK virus nephropathy
Posttransplant lymphoproliferative disorders
Calcineurin inhibitor nephrotoxicity
Acute tubular injury
Recurrent disease
De novo glomerulopathy (other than transplant glomerulopathy)
Pyelonephritis
Drug-induced interstitial nephritis
ABMR, antibody-mediated rejection; cg, glomerular double contours; DSA, donor-specific antibody; EM, electron microscopy;
g, glomerulitis; i, inflammation; IF, immunofluorescence; IHC, immunohistochemistry; ptc, peritubular capillaritis; t, tubulitis; TCMR,
T cell–mediated rejection; TG, transplant glomerulopathy; TMA, thrombotic microangiopathy; v, intimal arteritis.
1It should be noted that these arterial lesions may be indicative of ABMR, TCMR, or mixed ABMR/TCMR. The v lesions are only
scored in arteries having a continuous media with two or more smooth muscle layers.
2Lesions of chronic, active ABMR can range from primarily active lesions with early TG evident only by EM (cg1a) to those with
advanced TG and other chronic changes in addition to active microvascular inflammation. In the absence of evidence of current/recent
antibody interaction with the endothelium (those features in the second section of Table 3), the term “active” should be omitted; in
such cases, DSAs may be present at the time of biopsy or at any previous time after transplantation.
3Seven or more layers in one cortical peritubular capillary and five or more in two additional capillaries, avoiding portions cut tangentially.
4The clinical significance of these findings may be quite different in grafts exposed to anti–blood group antibodies (ABO-incompatible
allografts), in which they do not appear to be injurious to the graft and may represent accommodation; however, with anti-HLA anti-
bodies, such lesions may progress to chronic ABMR and more outcome data are needed.
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Table 4: Banff lesion grading system
Lesions
Quantitative criteria for inflammation: i score
i0 No inflammation or in <10% of unscarred cortical parenchyma
i1 Inflammation in 10–25% of unscarred cortical parenchyma
i2 Inflammation in 26–50% of unscarred cortical parenchyma
i3 Inflammation in >50% of unscarred cortical parenchyma
Quantitative criteria for tubulitis: t score
t0 No mononuclear leukocytes in tubules
t1 Foci with one to four leukocytes per tubular cross-section (or 10 tubular cells)
t2 Foci with five to 10 leukocytes per tubular cross-section (or 10 tubular cells)
t3 Foci with >10 leukocytes per tubular cross-section or the presence of two or more areas of tubular basement
membrane destruction accompanied by i2/i3 inflammation and t2 elsewhere
Quantitative criteria for intimal arteritis: v score
v0 No arteritis
v1 Mild to moderate intimal arteritis in at least one arterial cross-section
v2 Severe intimal arteritis with at least 25% luminal area lost in at least one arterial cross-section
v3 Transmural arteritis and/or arterial fibrinoid change and medial smooth muscle necrosis with lymphocytic infiltrate
in vessel
Quantitative criteria for glomerulitis: g score
g0 No glomerulitis
g1 Glomerulitis in <25% of glomeruli
g2 Segmental or global glomerulitis in 25–75% of glomeruli
g3 Glomerulitis in >75% of glomeruli
Quantitative criteria for peritubular capillaritis: ptc score
ptc0 At least one leukocyte in <10% of cortical PTCs and/or maximum number of leukocytes <3
ptc1 At least one leukocyte cell in ≥10% of cortical PTCs with three or four leukocytes in most severely involved PTC
ptc2 At least one leukocyte in ≥10% of cortical PTCs with five to 10 leukocytes in most severely involved PTC
ptc3 At least one leukocyte in ≥10% of cortical PTCs with >10 leukocytes in most severely involved PTC
Quantitative criteria for total inflammation: ti score
ti0 No or trivial interstitial inflammation (<10% of total cortical parenchyma)
ti1 10–25% of total cortical parenchyma inflamed
ti2 26–50% of total cortical parenchyma inflamed
ti3 >50% of total cortical parenchyma inflamed
Quantitative criteria for inflammation in area of interstitial fibrosis and tubular atrophy: i-IFTA score
i-IFTA0 No inflammation or <10% of scarred cortical parenchyma
i-IFTA1 Inflammation in 10–25% of scarred cortical parenchyma
i-IFTA2 Inflammation in 26–50% of scarred cortical parenchyma
i-IFTA3 Inflammation in >50% of scarred cortical parenchyma
Quantitative criteria for C4d score
C4d0 No staining of PTCs (0%)
C4d1 Minimal C4d staining (>0 but <10% of PTCs)
C4d2 Focal C4d staining (10–50% of PTCs)
C4d3 Diffuse C4d staining (>50% of PTCs)
Quantitative criteria for double contour: cg score
cg0 No GBM double contours by light microscopy or EM
cg1a No GBM double contours by light microscopy but GBM double contours (incomplete or circumferential) in at least
three glomerular capillaries by EM, with associated endothelial swelling and/or subendothelial electron-lucent
widening
cg1b Double contours of the GBM in 1–25% of capillary loops in the most affected nonsclerotic glomerulus by light
microscopy; EM confirmation is recommended if EM is available
cg2 Double contours affecting 26–50% of peripheral capillary loops in the most affected glomerulus
cg3 Double contours affecting >50% of peripheral capillary loops in the most affected glomerulus
Quantitative criteria for mesangial matrix expansion: mm score
mm0 No more than mild mesangial matrix increase in any glomerulus
mm1 At least moderate mesangial matrix increase in up to 25% of nonsclerotic glomeruli
mm2 At least moderate mesangial matrix increase in 26–50% of nonsclerotic glomeruli
mm3 At least moderate mesangial matrix increase in >50% of nonsclerotic glomeruli
(Continued )
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(i.e. overimmunosuppression) and the detrimental impact
of further disease progression (i.e. underimmunosuppres-
sion). A potential path forward would be to generate con-
sensus in molecular transplant diagnostics regarding
which molecules are assessed or quantified in what set-
tings (Table 5) and then to develop clinically relevant
diagnostic thresholds through retrospective and prospec-
tive multicenter validation studies based on standardized
assessment of the same molecular lesions in the same
clinical context. This approach would be analogous to
the Banff consensus process in 1991 for morphologic
lesions. Previous research revealed strong associations
between certain molecular pathways and well-
established Banff histologic lesions (Figure 1). These key
molecular pathways can be represented and thus
assessed by relatively few molecules from each path-
way, either through quantification of respective gene
sets or through summarizing such genes in weighted
equations as diagnostic classifiers. Generating consensus
for sets of molecules or classifiers reflecting certain bio-
logical or disease processes related to the established
histologic Banff lesions would enable us to assess and
validate their clinical value. In this regard, the most
robust evidence is currently available for the association
Table 4. Continued
Lesions
Quantitative criteria for arteriolar hyalinosis: ah score
ah0 No PAS-positive hyaline arteriolar thickening
ah1 Mild to moderate PAS-positive hyaline thickening in at least one arteriole
ah2 Moderate to severe PAS-positive hyaline thickening in more than one arteriole
ah3 Severe PAS-positive hyaline thickening in many arterioles
Alternative quantitative criteria for hyaline arteriolar thickening: aah score
aah0 No typical lesions of calcineurin inhibitor–related arteriolopathy
aah1 Replacement of degenerated smooth muscle cells by hyaline deposits in only one arteriole, without circumferential
involvement
aah2 Replacement of degenerated smooth muscle cells by hyaline deposits in more than one arteriole, without
circumferential involvement
aah3 Replacement of degenerated smooth muscle cells by hyaline deposits with circumferential involvement, independent
of the number of arterioles involved.
Quantitative criteria for vascular fibrous intimal thickening: cv score
cv0 No chronic vascular changes
cv1 Vascular narrowing of up to 25% luminal area by fibrointimal thickening
cv2 Vascular narrowing of 26–50% luminal area by fibrointimal thickening
cv3 Vascular narrowing of >50% luminal area by fibrointimal thickening
Quantitative criteria for interstitial fibrosis: ci score
ci0 Interstitial fibrosis in up to 5% of cortical area
ci1 Interstitial fibrosis in 6–25% of cortical area (mild interstitial fibrosis)
ci2 Interstitial fibrosis in 26–50% of cortical area (moderate interstitial fibrosis)
ci3 Interstitial fibrosis in >50% of cortical area (severe interstitial fibrosis)
Quantitative criteria for tubular atrophy: ct score
ct0 No tubular atrophy
ct1 Tubular atrophy involving up to 25% of the area of cortical tubules (mild tubular atrophy)
ct2 Tubular atrophy involving 26–50% of the area of cortical tubules (moderate tubular atrophy)
ct3 Tubular atrophy involving in >50% of the area of cortical tubules (severe tubular atrophy)
aah, hyaline arteriolar thickening; ah, arteriorlar hyalinosis; cg, glomerular double contours; ci, interstitial fibrosis; ct, tubular atrophy;
cv, vascular fibrous intimal thickening; EM, electron microscopy; g, glomerulitis; GBM, glomerular basement membrane; i, inflamma-
tion; i-IFTA, interstitial inflammation in areas of interstitial fibrosis and tubular atrophy; mm, mesangial matrix expansion; PAS, periodic
acid–Schiff; ptc, peritubular capillaritis; PTC, peritubular capillary; t, tubulitis; v, intimal arteritis.
Table 5: Key areas for which consensus needs to be generated
and validated to adopt molecular diagnostics into the Banff clas-
sification
Indication Applications Methods
Diagnosis Tissue/biopsy Targets
TCMR
ABMR
Injury, acute
Injury, chronic
Biopsies for cause
Protocol biopsies
mRNA
miRNA
Free DNA
Proteins
Metabolites
Body fluids
Urine
Blood
Bile
Prediction (prognosis)
Failure
Initial function/DGF
Response to treatment
(companion diagnostic)
Platforms
PCR
Microarrays
ELISA
Flow
NanoString
Luminex
IHC
Other
Treatment monitoring
Response to treatment
(after treatment)
Side effects/dosing
Trial end point
ABMR, antibody-mediated rejection; DGF, delayed graft func-
tion; ELISA, enzyme-linked immunosorbent assay; IHC,
immunohistochemistry; mRNA, messenger RNA; miRNA,
microRNA; PCR, polymerase chain reaction; TCMR, T cell–
mediated rejection.
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among antibody-mediated injury; microcirculation inflam-
mation; and increased expression of endothelial, NK cell,
and inflammation-associated transcripts in the allograft
(29,54,55,56).
Discussion of the above approach took place at the 2015
Banff meeting and continued afterward via e-mail
exchange among the key opinion leaders. From these
interactions, key next steps toward adopting molecular
diagnostics into transplantation pathology were identified
and are summarized (Table 6):
1. The overwhelming majority of those who commented
support pursuing the generation of molecular consen-
sus gene sets (or classifiers) from the overlap between
published gene lists, adding key genes based on
pathogenesis-based association with the main clinical
indications and phenotypes (TCMR, ABMR).
2. More collaborative multicenter studies are needed
(Table 6) to close existing knowledge gaps before
Banff can “officially” adopt specific molecular diag-
nostics as part of the classification.
3. Consensus must be generated on gene sets, which
can be studied further in a multicenter setting.
4. Results from such studies should be reviewed at
future Banff meetings as part of an ongoing consen-
sus process for molecular diagnostics.
Once consensus for gene sets and/or classifiers for
molecular biopsy assessment is achieved, prospective
and retrospective validation trials can be initiated. Similar
to the validation of histologic Banff lesions and diagnostic
rules established in 1991, only multicenter validation of
different diagnostic approaches with hard clinical end
points (e.g. allograft survival, response to treatment) can
Figure 1: Molecular lesions and their corresponding histologic lesions in T cell–mediated rejection and antibody-mediated
rejection in kidney allografts. cg, glomerular double contours; cv, vascular fibrous intimal thickening; i, inflammation; ptc, peritubular
capillaritis; ti, total inflammation; v, intimal arteritis.
Table 6: Identified knowledge gap in the adoption process for
molecular transplant diagnostics
ABMR
Comparison of subclinical ABMR versus clinical ABMR
Comparison of DSA-negative biopsies versus DSA-positive
biopsies in sequence from the same patient
Comparison of matched biopsies from adherent versus
nonadherent patients
Comparison of histologically similar biopsies from patients
with anti-HLA versus non-HLA antibody ligands mediating
ABMR; define the molecular and histologic phenotypes of
ABMR mediated by non-HLA antibodies
Comparison of ABMR biopsies with TMA to TMA in native
kidneys
Comparison of consensus gene sets to diagnostic ABMR
classifiers
TCMR
Comparison of TCMR with and without DSA but no
glomerulitis or TG (note: ptc is often seen with TCMR)
Comparison of early versus late TCMR with different levels of
Banff i, t, and i-IFTA scores
Define the molecular phenotype of borderline cases in the
current clinical context, (i.e. after elimination of ABMR and
mixed cases)
Comparison of consensus gene sets to diagnostic TCMR
classifiers
Mixed rejection
Should be a focus because recent data suggest that most
cases of ABMR (at least in nonsensitized, nonadherent
patients) are mixed rejection
Testing the utility of one common rejection gene signature or
classifier versus two separate classifiers for ABMR and
TCMR in mixed cases
ABMR, antibody-mediated rejection; DSA, donor-specific anti-
body; i, inflammation; i-IFTA, interstitial inflammation in areas of
interstitial fibrosis and tubular atrophy; ptc, peritubular capillaritis;
t, tubulitis; TCMR, T cell–mediated rejection; TG, transplant
glomerulopathy; TMA, thrombotic microangiopathy.
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establish clinically useful diagnostic thresholds. In the
absence of a true diagnostic gold standard, adoption of
molecular diagnostics can only be accomplished in a
stepwise and iterative approach over time including
constant revisiting and refinement of current molecular
consensus as new knowledge emerges.
Summary of the Banff Pancreas Session
Three main topics (Table 7) were emphasized at the pan-
creas transplant session: (i) discussion of controversial
morphologic aspects, (ii) progress made with the working
groups since the 2013 meeting, and (iii) encouragement
Table 7: Updated Banff pancreas allograft rejection grading schema
1. Normal
• Absent inflammation or inactive septal, mononuclear inflammation not involving ducts, veins, arteries, or acini
• No graft sclerosis
• The fibrous component is limited to normal septa, and its amount is proportional to the size of the enclosed structures (ducts and
vessels). The acinar parenchyma shows no signs of atrophy or injury
2. Indeterminate
Septal inflammation that appears active, but the overall features do not fulfill the criteria for mild acute rejection
3. Acute TCMR
• Grade I (mild acute TCMR):
o Active septal inflammation (activated blastic lymphocytes and/or eosinophils) involving septal structures: venulitis (subendothelial
accumulation of inflammatory cells and endothelial damage in septal veins), ductitis (epithelial inflammation and damage of
ducts)
and/or
o Focal acinar inflammation (two or fewer foci per lobule) with absent or minimal acinar cell injury.
• Grade II (moderate acute TCMR [requires differentiation from ABMR]):
o Multifocal (but not confluent or diffuse) acinar inflammation (three or more foci per lobule) with spotty (individual) acinar cell
injury and dropout
and/or
o Mild intimal arteritis (with minimal [<25%] luminal compromise)
• Grade III (severe acute TCMR [requires differentiation from ABMR]):
o Diffuse (widespread, extensive) acinar inflammation with focal or diffuse multicellular/confluent acinar cell necrosis
and/or
o Moderate or severe intimal arteritis (>25% luminal compromise)
and/or
o Transmural inflammation—necrotizing arteritis
4. Acute/active ABMR
One of three diagnostic components: requires exclusion of ABMR
Two of three diagnostic components: consider acute ABMR
Three of three diagnostic components: definite acute ABMR
Diagnostic components:
a Histologic evidence of acute tissue injury:
• Grade I (mild acute ABMR): Well-preserved architecture, mild interacinar monocytic-macrophagic or mixed (monocytic-
macrophagic/neutrophilic) infiltrates with rare acinar cell damage (swelling, necrosis)
• Grade II (moderate acute ABMR): Overall preservation of the architecture with interacinar monocytic-macrophagic or mixed
(monocytic-macrophagic/neutrophilic) infiltrates, capillary dilatation, interacinar capillaritis, intimal arteritis,1 congestion, multicel-
lular acinar cell dropout, and extravasation of red blood cells
• Grade III (severe acute ABMR): Architectural disarray, scattered inflammatory infiltrates in a background of interstitial hemor-
rhage, multifocal and confluent parenchymal necrosis, arterial and venous wall necrosis, transmural/necrotizing arteritis,1 and
thrombosis (in the absence of any other apparent cause)
b C4d positivity in interacinar capillaries (≥1% of acinar lobular surface for immunohistochemistry)
c Serologic evidence of DSA (HLA or other antigens)
5. Chronic active ABMR
Combined features of category 3 and/or 4 with active chronic arteriopathy2 and/or category 6
Specify whether TCMR, ABMR, or mixed
6. Chronic arteriopathy3
• Fibrointimal arterial thickening with narrowing of the lumen
o Inactive: fibrointimal arterial thickening with narrowing of the lumen
o Active: infiltration of the subintimal fibrous proliferation by mononuclear cells (T cells and macrophages)
• Distinguish on the most affected artery:
o Grade 0, negative: no narrowing of the luminal area
o Grade 1, mild: ≤25% narrowing of luminal area
o Grade 2, moderate: 26–50% narrowing of luminal area
o Grade 3, severe: ≥50% narrowing of luminal area
(Continued )
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of data regarding the utility of endoscopic duodenal cuff
biopsies as surrogates of biopsies of the pancreas trans-
plant. Data were presented showing that a normal duode-
nal cuff biopsy accurately predicts absence of TCMR in
the pancreas parenchyma. A study of duodenal cuff biop-
sies showed a high incidence of cytomegalovirus infec-
tion in these samples that we do not know how to
interpret at this stage. Furthermore, data from detailed
morphologic studies on pale acinar nodules in native and
transplant pancreas biopsies, which are still of unclear eti-
ology and clinical significance, were presented (57). A
study was presented at the Banff session that showed
simultaneous pancreas and kidney transplant biopsies
demonstrating high concurrence between acute ABMR in
both organs and significant discrepancy between organs
for TCMR. Modifications to the Banff pancreas allograft
pathology schema were made after consensus was
reached following e-mail circulation to the BWG for Pan-
creas Pathology and via discussions during the meeting.
Main updates include incorporation of acute ABMR grad-
ing, improved definitions for TCMR and ABMR, specifica-
tion of vascular lesions, and inclusion of b cell islet
toxicity in the category of islet pathology. In the second
part of the session, key opinion leaders discussed
morphologic and clinical aspects of graft loss in whole
pancreas transplants as well as islet transplantation. It
was concluded that better understanding of the etiology
of graft loss represents an unmet need. This will require
systematic integration of morphologic (pathology), sero-
logic (DSAs and autoantibodies), and clinical–functional
(e.g. oral glucose tolerance test) parameters for study-
ing the cause and incidence of pancreas transplant
failure.
Summary of the VCA Session
The VCA session included speaker presentations and
discussion. Focal points of the former were ABMR after
face transplantation (58), graft vasculopathy in the skin
(59), cutaneous changes among transplant patients, and
the expansion of the Banff VCA scoring system. The
discussion included challenges to the Banff VCA sys-
tem, immunohistochemistry markers, specimen ade-
quacy, and differential diagnoses. Collaborative efforts
were discussed, and the working group concentrated
on the standardization of a document for the retrospec-
tive and prospective collection of data. The group will
reconvene at an international workshop on VCA
histopathology with the goals of continuing discussions
of the refinement of the Banff VCA system, the stan-
dardized form, and the development of a consensus
document that would be accessible worldwide. The goal
is to compile data and to review it at the Banff 2017
meeting.
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Table 7. Continued
7. Chronic graft fibrosis
• Grade I (mild graft fibrosis): Expansion of fibrous septa; the fibrosis occupies <30% of the core surface but the acinar lobules have
eroded, irregular contours. The central lobular areas are normal
• Grade II (moderate graft fibrosis): The fibrosis occupies 30–60% of the core surface. The exocrine atrophy affects the majority of
the lobules in their periphery (irregular contours) and in their central areas (thin fibrous strands criss-cross between individual acini)
• Grade III (severe graft fibrosis): The fibrotic areas predominate and occupy >60% of the core surface with only isolated areas of
residual acinar tissue and/or islets present
8. Islet pathology
• Recurrence of autoimmune diabetes mellitus (insulitis and/or selective b cell loss)
• Islet amyloid (amylin) deposition
• Islet cell calcineurin inhibitor toxicity
9. Other histologic diagnosis
Pathologic changes not considered to be caused by acute and/or chronic rejection (e.g. cytomegalovirus pancreatitis, posttransplant
lymphoproliferative disorder)
Categories 2 to 9 may be diagnosed concurrently and should be listed in the diagnosis in the order of their clinicopathologic signifi-
cance. See Drachenberg et al (61) for morphologic definition of lesions of cell-mediated rejection and for a list of other histologic diag-
noses. ABMR, antibody-mediated rejection; DSA, donor-specific antibody; TCMR, T cell–mediated rejection. Histologic features of
stereotypical TCMR and ABMR, see Table 3 in Drachenberg et al (60).
1Arteritis is not required for the diagnosis of ABMR but can be seen in ABMR as well as TCMR.
2Inactive chronic arteriopathy can also be included if there is evidence to suggest it is of new onset.
3The pathology report should specify how many medium and large arteries were sampled.
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